We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights: Microsoft, JPMorgan, AstraZeneca, Keurig Dr Pepper and Phillips 66
Read MoreHide Full Article
For Immediate Release
Chicago, IL – August 18, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Microsoft Corporation (MSFT - Free Report) , JPMorgan Chase & Co. (JPM - Free Report) , AstraZeneca PLC (AZN - Free Report) , Keurig Dr Pepper Inc. (KDP - Free Report) and Phillips 66 (PSX - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Research Reports for Microsoft, JPMorgan and AstraZeneca
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft, JPMorgan, and AstraZeneca. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of Microsoft have outperformed the S&P 500 over the past year (+40.7% vs. +35.8%). The Zacks analyst believes that it has been benefiting from strength in its Azure cloud platform. Teams' user growth is gaining from the pandemic-induced remote working scenario and the adoption of hybrid work models.
The company is also witnessing growth in the user base of its different applications including Microsoft 365 suite and Dynamics. Microsoft, however, expects Surface revenues to decline in the fiscal first quarter due to supply chain disruptions. Increased spending on Azure enhancements amid intensifying competition in the cloud space is likely to dent margins.
JPMorgan shares have gained +9.9% over the last six months against the Zacks Major Regional Banks industry's gain of +17.2%, but the bank's earnings beat the Zacks Consensus Estimate in each of the trailing four quarters. The Zacks analyst believes that strategic buyouts, global expansion, digitization initiatives, and decent mortgage banking business will keep supporting its financials.
JPMorgan's impressive capital deployments indicate its earnings strength as well as a solid balance sheet. Such factors are likely to enhance shareholder value. The pandemic-induced economic downturn is weighing heavily on the loan demand; however, a robust economic recovery might lead to rise in demand for loans. Steadily rising expenses also remain a concern.
Shares of AstraZeneca have gained +5.4% in the past three months against the Zacks Large Cap Pharmaceuticals industry's gain of +11.9%, however, the company's Q2 earnings were in line with estimates while sales beat the same.
The Zacks analyst believes that AstraZeneca stands to benefit from a strong diversified portfolio, an expanding presence in emerging markets, ongoing cost-cutting initiatives and a robust pipeline. The Alexion buyout strengthens its immunology franchise, adding several drugs that are likely to boost its top line. It's diabetes franchise, however, faces stiff competition while pricing pressure is hurting sales in the respiratory unit.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights: Microsoft, JPMorgan, AstraZeneca, Keurig Dr Pepper and Phillips 66
For Immediate Release
Chicago, IL – August 18, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Microsoft Corporation (MSFT - Free Report) , JPMorgan Chase & Co. (JPM - Free Report) , AstraZeneca PLC (AZN - Free Report) , Keurig Dr Pepper Inc. (KDP - Free Report) and Phillips 66 (PSX - Free Report) .
Here are highlights from Tuesday’s Analyst Blog:
Top Research Reports for Microsoft, JPMorgan and AstraZeneca
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Microsoft, JPMorgan, and AstraZeneca. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Shares of Microsoft have outperformed the S&P 500 over the past year (+40.7% vs. +35.8%). The Zacks analyst believes that it has been benefiting from strength in its Azure cloud platform. Teams' user growth is gaining from the pandemic-induced remote working scenario and the adoption of hybrid work models.
The company is also witnessing growth in the user base of its different applications including Microsoft 365 suite and Dynamics. Microsoft, however, expects Surface revenues to decline in the fiscal first quarter due to supply chain disruptions. Increased spending on Azure enhancements amid intensifying competition in the cloud space is likely to dent margins.
(You can read the full research report on Microsoft here >>>)
JPMorgan shares have gained +9.9% over the last six months against the Zacks Major Regional Banks industry's gain of +17.2%, but the bank's earnings beat the Zacks Consensus Estimate in each of the trailing four quarters. The Zacks analyst believes that strategic buyouts, global expansion, digitization initiatives, and decent mortgage banking business will keep supporting its financials.
JPMorgan's impressive capital deployments indicate its earnings strength as well as a solid balance sheet. Such factors are likely to enhance shareholder value. The pandemic-induced economic downturn is weighing heavily on the loan demand; however, a robust economic recovery might lead to rise in demand for loans. Steadily rising expenses also remain a concern.
(You can read the full research report on JPMorgan here >>>)
Shares of AstraZeneca have gained +5.4% in the past three months against the Zacks Large Cap Pharmaceuticals industry's gain of +11.9%, however, the company's Q2 earnings were in line with estimates while sales beat the same.
The Zacks analyst believes that AstraZeneca stands to benefit from a strong diversified portfolio, an expanding presence in emerging markets, ongoing cost-cutting initiatives and a robust pipeline. The Alexion buyout strengthens its immunology franchise, adding several drugs that are likely to boost its top line. It's diabetes franchise, however, faces stiff competition while pricing pressure is hurting sales in the respiratory unit.
(You can read the full research report on AstraZeneca here >>>)
Other noteworthy reports we are featuring today include Keurig Dr Pepper and Phillips 66.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.